BioPharmSignal logoBioPharmSignal

Biotech News

SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026

Si-Bone (SIBN)Si-BoneEarnings

SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended

Related news

SIBNSi-Bone2026-02-23 21:09 EST

SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance

SIBNSi-Bone2026-08-03 20:09 EST

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance

View all latest news

Si-Bone

Spinopelvic Procedural Solutions SI-BONE is a global medical-device company developing procedural solutions for patients with compromised bone, with a particular focus on the sacropelvic and spinopelvic anatomy. iFuse Technology Platform Its portfolio is built around the iFuse family of implants and instruments. Products include...

Recent company news

SIBNSi-Bone2026-08-03 20:09 EST

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance

SIBNSi-Bone2026-07-20 20:09 EST

SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026

SIBNSi-Bone2026-06-04 20:09 EST

SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026

SIBNSi-Bone2026-05-11 20:09 EST

SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance

SIBNSi-Bone2026-04-30 20:09 EST

SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026

Stock data

Close
19.96 USD
Market cap
621.33M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States